Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

MESO vs BHVN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BHVN Captures Overall Composite Edge (40.7 SELL vs 34.6 SELL), While MESO Leads 3–2 on Growth & Valuation Pillars

BHVN Overall Winner 6-Pillar Tally: MESO 3 – 2 BHVN (1 Tie) Matrix Metrics: MESO 3 – 5 BHVN

As of Nov 16, 2026, Biohaven Ltd. (BHVN) captures the overall head-to-head institutional edge over Mesoblast Limited (MESO) on higher Unified Composite conviction (40.7/100 SELL vs. 34.6/100 SELL) after splitting the core matrix 5–3 (led by Profitability & Quality, Options & Positioning), while MESO wins 3–2 across the 6-pillar growth and valuation breakdown. MESO trades at $12.47 (N/M Forward P/E, -42.6% operating margin) versus BHVN at $13.90 (N/M Forward P/E, 0.0% operating margin).

  • Growth vs. Quality Trade-Off: BHVN earns the overall head-to-head edge with a stronger Unified Composite Score (40.7/100 SELL vs. MESO 34.6/100 SELL) and 1.41β · 111% Vol risk profile, whereas MESO leads top-line expansion (+390.7% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
  • Defensive Composite Rating Caution: Although BHVN compares more favorably head-to-head, both MESO (34.6/100 SELL) and BHVN (40.7/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: MESO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.0); meanwhile BHVN is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MESO vs BHVN
MESO NASDAQ
Mesoblast Limited American Depositary Shares
Biological Products, (No Diagnostic Substances)
$12.47
-6.03% 1D
Market Cap $1.7B
TTM Revenue $120M
Forward P/E N/M
Beta / 30D Vol 1.18β · 78% Vol
Unified Composite Score
34.6 / 100 SELL
Tech 25.0 Fund 40.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -8.5%), weak momentum, RSI 39
RSI-14: 39.0 · SMA20: $13.64 · SMA50: $14.22
BHVN NYSE Head-to-Head Winner
Biohaven Ltd.
Pharmaceutical Preparations
$13.90
+0.62% 1D
Market Cap $2.1B
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.41β · 111% Vol
Unified Composite Score
40.7 / 100 SELL
Tech 15.0 Fund 42.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -0.9%) with fading momentum, RSI 49
RSI-14: 49.2 · SMA20: $14.56 · SMA50: $13.49

6-Pillar Scorecard Institutional Category Breakdown (MESO 3 – 2 BHVN)

Columns: Metric · MESO · BHVN
1. Valuation Multiples MESO
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 14.1x N/M
2. Growth & Scale MESO
Revenue Growth (YoY) +390.7% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $120M N/A
Market Cap $1.7B $2.1B
3. Profitability & Quality BHVN
Gross Margin 80.0% N/A
Operating Margin -42.6% 0.0%
Net Profit Margin -47.8% 0.0%
Return on Equity (ROE) -9.9% -799.5%
4. Balance Sheet & Cash Flow MESO
Cash Generation (TTM) -$45M EBITDA -$473M
Cash Flow Margin -37.1% EBITDA Mgn N/A
Net Cash / Leverage $4.38 Book/Sh · -9.9% ROE $205M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning BHVN
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 76.8% (37th %ile) 91.5% (18th %ile)
Put/Call OI Skew Thin ADR Chain 0.31x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Distribution
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MESO (3) vs BHVN (5)
Institutional Metric MESO BHVN Criterion Row Edge
Market Capitalization
Scale
$1.7B $2.1B Larger Scale BHVN
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+390.7% +0.0% Higher Growth MESO
Operating Margin (TTM)
Profitability
-42.6% 0.0% Higher Margin BHVN
Net Profit Margin
Profitability
-47.8% 0.0% Higher Margin BHVN
Return on Equity (ROE)
Capital Efficiency
-9.9% -799.5% Higher ROE MESO
52-Week Range Position
Momentum
6% ($12–$22) 59% ($8–$18) Stronger Trend BHVN
Beta / 30D Volatility
Risk Regime
1.18β · 78% Vol 1.41β · 111% Vol Lower Realized Risk MESO
Unified Institutional Score
Composite Signal
34.6 / 100 (SELL) 40.7 / 100 (SELL) Higher Composite BHVN
Trailing 12M Revenue (USD)
Operating Scale
$120M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
80.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 14.1x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$45M EBITDA ($4.38 Book/Sh · -9.9% ROE) -$473M ($205M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BHVN +35.09 pp
MESO: -6.1% · BHVN: +28.99%
3M Horizon BHVN +27.66 pp
MESO: -25.19% · BHVN: +2.47%
6M Horizon BHVN +78.6 pp
MESO: -14.82% · BHVN: +63.78%
1Y Horizon BHVN +88.51 pp
MESO: -16.42% · BHVN: +72.09%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MESO vs BHVN. Trailing 12-month operating profitability (MESO -42.6% vs BHVN 0.0%) and valuation multiples (MESO N/M vs BHVN N/M Forward P/E) are benchmarked directly in Pillar 4 below.

MESO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$120M
Gross Margin80.0%
Op. Margin-42.6%
ROE / Fwd P/E-9.9% · N/M
BHVN ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-799.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MESO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 76.8%
IV Percentile 37th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MESO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BHVN CONSOLIDATION
91d in phase · OBV NEUTRAL
Current IV 91.5%
IV Percentile 18th %ile
Put/Call OI Skew 0.31x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact BHVN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MESO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.7B market capitalization and -42.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
BHVN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.1B market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MESO vs BHVN Key Questions & Quantitative Answers

As of Nov 16, 2026, Biohaven Ltd. (BHVN) captures the overall head-to-head institutional edge over Mesoblast Limited (MESO) on higher Unified Composite conviction (40.7/100 SELL vs. 34.6/100 SELL) after splitting the core matrix 5–3 (led by Profitability & Quality, Options & Positioning), while MESO wins 3–2 across the 6-pillar growth and valuation breakdown. MESO trades at $12.47 (N/M Forward P/E, -42.6% operating margin) versus BHVN at $13.90 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: BHVN earns the overall head-to-head edge with a stronger Unified Composite Score (40.7/100 SELL vs. MESO 34.6/100 SELL) and 1.41β · 111% Vol risk profile, whereas MESO leads top-line expansion (+390.7% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Defensive Composite Rating Caution: Although BHVN compares more favorably head-to-head, both MESO (34.6/100 SELL) and BHVN (40.7/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: MESO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.0); meanwhile BHVN is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MESO leads the Growth & Scale pillar: MESO posts +390.7% YoY revenue growth and +0.0% YoY earnings growth on $120M TTM revenue (80.0% gross margin, -42.6% operating margin), compared with BHVN at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, MESO generates $120M in USD-normalized revenue versus N/A for BHVN. In operating R&D and SG&A reinvestment, MESO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BHVN.

MESO screens cheaper on headline valuation multiples. MESO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 14.1x EV/Revenue (-37.1% EBITDA margin), whereas BHVN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MESO (-9.9% ROE) versus BHVN (-799.5% ROE) capital efficiency.

In options market volatility and institutional positioning, MESO carries 76.8% implied volatility (37th %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.18β · 78% Vol realized risk). By comparison, BHVN carries 91.5% implied volatility (18th %ile, Compressed (<25th %ile)), a 0.31x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.41β · 111% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.